Zobrazeno 1 - 10
of 77
pro vyhledávání: '"A. M. Beaufort"'
Autor:
Elisabeth M. Jongbloed, Maurice P. H. M. Jansen, Vanja de Weerd, Jean A. Helmijr, Corine M. Beaufort, Marcel J. T. Reinders, Ronald van Marion, Wilfred F. J. van IJcken, Gabe S. Sonke, Inge R. Konings, Agnes Jager, John W. M. Martens, Saskia M. Wilting, Stavros Makrodimitris
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Next generation sequencing of cell-free DNA (cfDNA) is a promising method for treatment monitoring and therapy selection in metastatic breast cancer (MBC). However, distinguishing tumor-specific variants from sequencing artefacts and germlin
Externí odkaz:
https://doaj.org/article/25950c21f0c9448e94b13a8b82eb4ebd
Autor:
Silvia R. Vitale, Kirsten Ruigrok-Ritstier, A. Mieke Timmermans, Renée Foekens, Anita M. A. C. Trapman-Jansen, Corine M. Beaufort, Paolo Vigneri, Stefan Sleijfer, John W. M. Martens, Anieta M. Sieuwerts, Maurice P. H. M. Jansen
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-16 (2022)
Abstract Background In breast cancer (BC), recurrent fusion genes of estrogen receptor alpha (ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the ligand binding domain of ESR1 has been replaced by the transactivation dom
Externí odkaz:
https://doaj.org/article/5619f8611366419781ebf77950eb8c5c
Autor:
M. K. Bos, S. W. Lam, G. Motta, J. C. A. Helmijr, C. M. Beaufort, E. de Jonge, J. W. M. Martens, E. Boven, M. P. H. M. Jansen, A. Jager, S. Sleijfer
Publikováno v:
Bos, M K, Lam, S W, Motta, G, Helmijr, J C A, Beaufort, C M, de Jonge, E, Martens, J W M, Boven, E, Jansen, M P H M, Jager, A & Sleijfer, S 2023, ' Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer ', Breast Cancer Research and Treatment, vol. 200, no. 2, pp. 271-279 . https://doi.org/10.1007/s10549-023-06965-5
Breast Cancer Research and Treatment, 200(2), 271-279. Springer New York
Breast Cancer Research and Treatment, 200(2), 271-279. Springer New York
Background ESR1 mutations have been identified as mechanism for endocrine resistance and are also associated with a decreased overall survival. We assessed ESR1 mutations in circulating tumor DNA (ctDNA) for impact on outcome to taxane-based chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7aebbcd0120eb600dc370a3b31b7216
https://pure.eur.nl/en/publications/00ba171e-1ab7-4e84-bef7-427b3ddafd1e
https://pure.eur.nl/en/publications/00ba171e-1ab7-4e84-bef7-427b3ddafd1e
Autor:
Anieta M. Sieuwerts, Wendy Onstenk, Jaco Kraan, Corine M. Beaufort, Mai Van, Bram De Laere, Luc Y. Dirix, Paul Hamberg, Aart Beeker, Hielke J. Meulenbeld, Geert‐Jan Creemers, Wytske M. vanWeerden, Guido W. Jenster, Annemieke J. M. Nieuweboer, Ron H. J. Mathijssen, Ronald deWit, John W. M. Martens, Stefan Sleijfer
Publikováno v:
Molecular Oncology, Vol 13, Iss 8, Pp 1795-1807 (2019)
The androgen receptor splice variant (AR‐V) 7 in circulating tumor cells (CTCs) is a predictor for resistance to anti‐AR‐targeted treatment, but not to taxane‐based chemotherapy in metastatic castration‐resistant prostate cancer (mCRPC). In
Externí odkaz:
https://doaj.org/article/9ca2c96fafc6462f975ce13bf278760c
Autor:
I. E. de Kruijff, A. M. Sieuwerts, N. Beije, W. J. C. Prager - van der Smissen, L. Angus, C. M. Beaufort, M. N. Van, E. Oomen - de Hoop, A. Jager, P. Hamberg, F. E. de Jongh, J. Kraan, J. W. M. Martens, S. Sleijfer
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundCisplatin (cDDP) has regained interest for metastatic breast cancer (MBC) patients, given the platinum sensitivity in subtypes and better manageable toxicity. Here, the primary aim was to determine whether molecular characteristics of circu
Externí odkaz:
https://doaj.org/article/3ecfd168a49445039557708262e8b2a4
Autor:
Marjolein J. A. Weerts, Ronald van Marion, Jean C. A. Helmijr, Corine M. Beaufort, Niels M. G. Krol, Anita M. A. C. Trapman-Jansen, Winand N. M. Dinjens, Stefan Sleijfer, Maurice P. H. M. Jansen, John W. M. Martens
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Abstract The use of blood-circulating cell-free DNA (cfDNA) as ‘liquid-biopsy’ is explored worldwide, with hopes for its potential in providing prognostic or predictive information in cancer treatment. In exploring cfDNA, valuable repositories ar
Externí odkaz:
https://doaj.org/article/569193aba5394563865fe2f9224685ca
Autor:
Silvia R. Vitale, Floris H. Groenendijk, Ronald van Marion, Corine M. Beaufort, Jean C. Helmijr, Hendrikus Jan Dubbink, Winand N. M. Dinjens, Patricia C. Ewing-Graham, Ramon Smolders, Helena C. van Doorn, Ingrid A. Boere, Els M. J. J. Berns, Jozien Helleman, Maurice P. H. M. Jansen
Publikováno v:
Biomolecules, Vol 10, Iss 3, p 415 (2020)
The aim of this study was to determine an optimal workflow to detect TP53 mutations in baseline and longitudinal serum cell free DNA (cfDNA) from high-grade serous ovarian carcinomas (HGSOC) patients and to define whether TP53 mutations are suitable
Externí odkaz:
https://doaj.org/article/76c9e3e5ee1348d4b952b7c5f009f099
Autor:
Ben M Eyck, Maurice PHM Jansen, Bo Jan Noordman, Peggy N Atmodimedjo, Berend J van der Wilk, John WM Martens, Jean A Helmijr, Corine M Beaufort, Bianca Mostert, Michail Doukas, Bas PL Wijnhoven, Sjoerd M Lagarde, J Jan B van Lanschot, Winand NM Dinjens
Publikováno v:
Journal of Pathology, 259(1), 35-45. John Wiley & Sons Ltd.
Active surveillance instead of standard surgery after neoadjuvant chemoradiotherapy (nCRT) has been proposed for patients with oesophageal cancer. Circulating tumour DNA (ctDNA) may be used to facilitate selection of patients for surgery. We show tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b401f403e19c23c9605465464203cfe
https://pubmed.ncbi.nlm.nih.gov/36196486
https://pubmed.ncbi.nlm.nih.gov/36196486
Autor:
Khrystany T. Isebia, Bianca Mostert, Bodine P.S. Belderbos, Stefan A.J. Buck, Jean C.A. Helmijr, Jaco Kraan, Corine M. Beaufort, Mai N. Van, Esther Oomen - de Hoop, Anieta M. Sieuwerts, Wilfred F.J. van IJcken, Mirjam C.G.N. van den Hout - van Vroonhoven, Rutger W.W. Brouwer, Edwin Oole, Paul Hamberg, Brigitte C.M. Haberkorn, Helgi H. Helgason, Ronald de Wit, Stefan Sleijfer, Ron H.J. Mathijssen, John W.M. Martens, Maurice P.H.M. Jansen, Job van Riet, Martijn P. Lolkema
Publikováno v:
European Journal of Cancer, 177, 33-44. Elsevier Ltd.
Background: Metastatic castration-resistant prostate cancer (mCRPC) patients with positive AR-V7 expression in their circulating tumour cells (CTCs) rarely derive benefit from abiraterone and enzalutamide. Design: We performed a prospective, multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e82668308c42e90ceccad60a316039c
https://pubmed.ncbi.nlm.nih.gov/36323051
https://pubmed.ncbi.nlm.nih.gov/36323051
Autor:
Stefan Sleijfer, John W.M. Martens, Harmen J.G. van de Werken, Corine M. Beaufort, Anieta M. Sieuwerts, Job van Riet, Nikolas H. Stoecklein, Jaco Kraan, Yorick Sandberg, Peter A. W. te Boekhorst, Martijn P. Lolkema, Wytske M. van Weerden, Anouk C. de Jong, Paul Hamberg, S. Erkens-Schulze, Lisanne F. van Dessel, L. Mout, Thomas L.C. Woo, Ronald de Wit, Rui P L Neves
Publikováno v:
European Journal of Cancer, 150, 179-189. Elsevier Ltd.
Background: Circulating tumour cell (CTC)–derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce1f4c8d8d0a5fc8b5f55e9aaea36dc4
https://doi.org/10.1016/j.ejca.2021.03.023
https://doi.org/10.1016/j.ejca.2021.03.023